TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24447110

Group type: EXPERIMENTAL
Intervention: 40% glycolic acid (GA) peels applied on half of the face, performed five times at 2-week intervals
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo applied on the other half of the face
Number of subjects: 26
Study: 22130792

Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg/d (group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium perchlorate 500 mg twice daily (group B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prednisone plus perchlorate (group C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 36
Study: 20639801

Group type: EXPERIMENTAL
Intervention: Anatomically shaped permanent expander implant McGhan Style 150
Number of subjects: 36

Group type: COMPARATOR
Intervention: Round permanent expander implant Siltex Becker 25
Number of subjects: 36
Study: 17931949

Group type: EXPERIMENTAL
Intervention: Immediate postoperative irradiation (60 Gy delivered over 6 weeks)
Number of subjects: 1005
Study: 15855572

Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 10883415

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg) administered orally during the follicular phase
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg) administered orally during the ovulatory phase
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg) administered orally during the luteal phase
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the follicular phase
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the ovulatory phase
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the luteal phase
Number of subjects: 11
Study: 9187068

Group type: EXPERIMENTAL
Intervention: G‐CSF (10 microg per kilogram of body weight per day subcutaneously)
Number of subjects: 164
Study: 1586602

Group type: EXPERIMENTAL
Intervention: Continuous low dose infusion of recombinant interleukin-2 (rIL-2) at doses of 0.18 x 10(6) IU, 0.6 x 10(6) IU, 1.8 x 10(6) IU, 3 x 10(6) IU, 6 x 10(6) IU, and 9 x 10(6) IU per m2 per 24 h.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Continuous low dose infusion of recombinant interleukin-2 (rIL-2) at a dose of 1.8 x 10(6) IU m-2 24 h-1.
Number of subjects: 22
Study: 31810484

Group type: EXPERIMENTAL
Intervention: PJIRSTR
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PJIRDTR
Number of subjects: 300

Group type: COMPARATOR
Intervention: TGRY
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PJIRSTR and PJIRDTR
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PJIRSTR, PJIRDTR, TGRY
Number of subjects: 300
Study: 29587851

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by Adalimumab
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 185
Study: 27756277

Group type: EXPERIMENTAL
Intervention: Jump Start intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (comparison)
Number of subjects: 0
Study: 23064254

Group type: EXPERIMENTAL
Intervention: Cumulative energy intake <689 kcal (average 63 kcal/kg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cumulative energy intake ≥689 kcal
Number of subjects: 32
Study: 20074020

Group type: EXPERIMENTAL
Intervention: Toremifene (20 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 48
Study: 18198271

Group type: EXPERIMENTAL
Intervention: Antidepressant use during follow-up
Number of subjects: 1191

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Initial rapid cycling status
Number of subjects: 1191
Study: 16617647

Group type: EXPERIMENTAL
Intervention: Soft Seal laryngeal mask airway
Number of subjects: 35

Group type: COMPARATOR
Intervention: Reusable laryngeal mask airway
Number of subjects: 35
Study: 12519797

Group type: EXPERIMENTAL
Intervention: Systematic reviews of acupuncture
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Systematic reviews of herbal medicines
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Systematic reviews of homeopathy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Inclusion criteria
Number of subjects: 17

Group type: COMPARATOR
Intervention: Literature searching methods
Number of subjects: 17
Study: 10958089

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% followed by ropivacaine 0.1% + 2 microg x ml(‐1) fentanyl infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: bupivacaine 0.25% followed by bupivacaine 0.125% + 2 microg x ml(‐1) fentanyl infusion
Number of subjects: 100
Study: 8659763

Group type: EXPERIMENTAL
Intervention: 0.2 microgram/kg T3 (n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline placebo (n = 18)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.2 microgram/kg T3 (n = 10) in patients with impaired left ventricular function
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline placebo (n = 10) in patients with impaired left ventricular function
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.2 microgram/kg T3 (n = 8) in patients with delayed organ harvesting
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline placebo (n = 9) in patients with delayed organ harvesting
Number of subjects: 37
Study: 1579324

Group type: EXPERIMENTAL
Intervention: E2 (75 mg) alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: E2 (75 mg) with testosterone (100 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (25 untreated women)
Number of subjects: 50
Study: 3536248

Group type: EXPERIMENTAL
Intervention: Povidone-iodine scrub and paint
Number of subjects: 101

Group type: COMPARATOR
Intervention: Povidone-iodine painting alone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Preoperative hexachlorophene showers
Number of subjects: 101
Study: 30175142

Group type: EXPERIMENTAL
Intervention: Same-gender games (SGG) for girls
Number of subjects: 134

Group type: COMPARATOR
Intervention: Mixed-gender games for girls
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Mixed-gender games for boys
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 2v2 small-sided games (SSG)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 4v4 small-sided games (SSG)
Number of subjects: 134

Group type: COMPARATOR
Intervention: 12v12 large-sided games (LSG)
Number of subjects: 134
Study: 26475356

Group type: EXPERIMENTAL
Intervention: Q3W group (capecitabine 1,000 mg/m² twice daily on days 1-14 and oxaliplatin 130 mg/m² on day 1 every 21 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Q2W group (capecitabine 2,000 mg/m² twice daily on days 1-7 and oxaliplatin 85 mg/m² on day 1 every 14 days)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Q3W group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Q2W group
Number of subjects: 46
Study: 25087417

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation using The Vest clearance system
Number of subjects: 30
Study: 22441532

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 813

Group type: COMPARATOR
Intervention: White Light Imaging (WLI)
Number of subjects: 813
Study: 20453564

Group type: EXPERIMENTAL
Intervention: Error reporting promoting strategy (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 18328059

Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream applied to the right hemi-face, twice daily for 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo cream applied to the left hemi-face, twice daily for 4 weeks
Number of subjects: 25
Study: 19143948

Group type: EXPERIMENTAL
Intervention: Clown presence during preoperative period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 0.5 mg x kg(‐1) oral 30 min before surgery (max 15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 15870633

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Water
Number of subjects: 27
Study: 11376505

Group type: EXPERIMENTAL
Intervention: Tramadol in continuous infusion (dose 12 mg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketorolac in continuous infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tramadol in repeated boluses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine in repeated boluses
Number of subjects: 60
Study: 9391249

Group type: EXPERIMENTAL
Intervention: Loxiglumide (LOX) infusion (66 mumol/kg/h for 10 min followed by 22 mumol/kg/h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Loxiglumide (LOX) infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8203853

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (400 mg every 8 h)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Imipenem (1,000 mg every 8 h)
Number of subjects: 405
Study: 2962087

Group type: EXPERIMENTAL
Intervention: Prophylactic ceftriaxone (group A)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No prophylactic ceftriaxone (group B)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 12172398

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 29037267

Group type: EXPERIMENTAL
Intervention: Tracking of dietary diversity score (DDS)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Meal frequency
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Intakes of Fe-rich foods
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Intakes of vitamin A-rich foods
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Socio-economic status
Number of subjects: 229
Study: 26833933

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic strategies for managing behavioral symptoms
Number of subjects: 110
Study: 25475461

Group type: EXPERIMENTAL
Intervention: Nonremote community hospitals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote community hospitals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tertiary care hospitals
Number of subjects: 0
Study: 22452413

Group type: EXPERIMENTAL
Intervention: Hypothermia (n = 23)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (n = 28)
Number of subjects: 51
Study: 19896383

Group type: EXPERIMENTAL
Intervention: Dynamic alignment in OA group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Knee adduction moment (KAM)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Health-related quality of life, habitual level of physical activity, lower extremity muscle strength and balance performance
Number of subjects: 34
Study: 18305231

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 15909670

Group type: EXPERIMENTAL
Intervention: Castor oil
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Bisacodyl
Number of subjects: 155

Group type: COMPARATOR
Intervention: Comparison of castor oil and bisacodyl
Number of subjects: 155
Study: 12885750

Group type: EXPERIMENTAL
Intervention: L-DOPS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Carbidopa (as a control)
Number of subjects: 19
Study: 9876215

Group type: EXPERIMENTAL
Intervention: 5 mg/day donepezil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg/day donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7583508

Group type: EXPERIMENTAL
Intervention: Parents of mentally retarded children
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Parents of children with neurological impairments
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched control group of parents of children without disabilities
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Parents of disabled children (both groups)
Number of subjects: 40
Study: 1787894

Group type: EXPERIMENTAL
Intervention: Heparan sulfate (200 mg/die, one 100 mg tablet twice a day) for 60 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 20
Study: 7270721

Group type: EXPERIMENTAL
Intervention: Hand-warming group (migraine patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hand-cooling group (migraine patients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hand-warming group (normal volunteers)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hand-cooling group (normal volunteers)
Number of subjects: 20
Study: 30165171

Group type: EXPERIMENTAL
Intervention: FMX101 4%
Number of subjects: 961

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 961
Study: 30091716

Group type: EXPERIMENTAL
Intervention: Cough sound analysis
Number of subjects: 322
Study: 27123448

Group type: EXPERIMENTAL
Intervention: RAT + real tDCS
Number of subjects: 23

Group type: COMPARATOR
Intervention: RAT + sham-tDCS
Number of subjects: 23
Study: 24825596

Group type: EXPERIMENTAL
Intervention: 6-month supervised exercise training
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 12-month supervised exercise training
Number of subjects: 94
Study: 22301528

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 110

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 110
Study: 20482825

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening with prior consultation either by telephone or outpatient clinic (5,000 persons)
Number of subjects: 7500

Group type: COMPARATOR
Intervention: CT colonography screening (2,500 persons)
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Colonoscopy following CT colonography positives
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 7500
Study: 18572993

Group type: EXPERIMENTAL
Intervention: Individual SMT
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Group SMT
Number of subjects: 82

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 82
Study: 15740544

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 15271871

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 11002380

Group type: EXPERIMENTAL
Intervention: 0.3 g/day of n-3 PUFA for 8 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.6 g/day of n-3 PUFA for 8 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.9 g/day of n-3 PUFA for 8 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0 g/day of n-3 PUFA for 8 weeks (placebo)
Number of subjects: 63
Study: 9496777

Group type: EXPERIMENTAL
Intervention: Acute attack drugs (sumatriptan, ergot derivatives, NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent prophylaxis with ergot derivatives or NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestrogen supplementation with percutaneous or transdermal oestradiol (100 microg patches)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioestrogen agents (danazol, tamoxifen)
Number of subjects: 0
Study: 1526079

Group type: EXPERIMENTAL
Intervention: Semisimultaneous method
Number of subjects: 8

Group type: COMPARATOR
Intervention: Stable isotope method
Number of subjects: 8
Study: 4014808

Group type: EXPERIMENTAL
Intervention: Calcium chloride
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Calcium chloride (in patients with widened QRS or ischemic changes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No calcium chloride (in patients with widened QRS or ischemic changes)
Number of subjects: 90
Study: 31320290

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate intravaginal ring
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 17
Study: 30027483

Group type: EXPERIMENTAL
Intervention: Fast-track protocol (FP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular protocol (RP)
Number of subjects: 50
Study: 27301741

Group type: EXPERIMENTAL
Intervention: Performance Based Financing (PBF) scheme applied to malnutrition services in half of the health centres
Number of subjects: 6480

Group type: COMPARATOR
Intervention: Budget allocation for malnutrition services in the other half of the health centres (Control)
Number of subjects: 6480
Study: 24767671

Group type: EXPERIMENTAL
Intervention: 6-week programme of exercise (3 sessions per week: 2 supervised, 1 unsupervised)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 22228235

Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine
Number of subjects: 3994
Study: 20413081

Group type: EXPERIMENTAL
Intervention: CD (youth intervention delivered by CD-ROM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD(P) (youth intervention plus parent intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 18616687

Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI) with naltrexone
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Medical Management (MM) plus placebo
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Combined Behavioral Intervention (CBI) with placebo
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Naltrexone with CBI
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Naltrexone without CBI
Number of subjects: 1226
Study: 16163639

Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir
Number of subjects: 70

Group type: COMPARATOR
Intervention: nelfinavir
Number of subjects: 70
Study: 12088971

Group type: EXPERIMENTAL
Intervention: Neutral position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Externally rotated position
Number of subjects: 20
Study: 9656287

Group type: EXPERIMENTAL
Intervention: Cycle video
Number of subjects: 12

Group type: COMPARATOR
Intervention: No video
Number of subjects: 12
Study: 8086325

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 2527532

Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril intravenous 5 micrograms kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril intravenous 20 micrograms kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril repeated administration for 8 days
Number of subjects: 0
Study: 63744

Group type: EXPERIMENTAL
Intervention: Intermittent compression of the arms during and after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patients (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent compression of the arms
Number of subjects: 0
Study: 29617758

Group type: EXPERIMENTAL
Intervention: Headgear (HG) treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (CG) - untreated
Number of subjects: 99
Study: 26486851

Group type: EXPERIMENTAL
Intervention: 25% energy deficit by calorie restriction alone (CR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 25% energy deficit by calorie restriction with structured exercise (CREX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: weight maintenance (control)
Number of subjects: 24
Study: 24810863

Group type: EXPERIMENTAL
Intervention: PFIT‐s
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MRC sum score
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Grip strength test
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Baseline test with ICU discharge
Number of subjects: 51
Study: 23124126

Group type: EXPERIMENTAL
Intervention: Open system suctioning (OS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Closed system suctioning (CS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both OS and CS
Number of subjects: 32
Study: 19501822

Group type: EXPERIMENTAL
Intervention: Withania somnifera treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (normal healthy fertile men)
Number of subjects: 75
Study: 18539917

Group type: EXPERIMENTAL
Intervention: Intensive therapy (targeting glycated hemoglobin level below 6.0%)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard therapy (targeting glycated hemoglobin level from 7.0 to 7.9%)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 10251
Study: 16038713

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg plus acetylsalicylic acid 75 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Extended-release dipyridamole 200 mg plus acetylsalicylic acid 25 mg
Number of subjects: 23
Study: 12096265

Group type: EXPERIMENTAL
Intervention: Color-flow duplex (CFD) scan
Number of subjects: 79

Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 79
Study: 10090427

Group type: EXPERIMENTAL
Intervention: Loading-dose metrifonate (100 mg or 150 mg for 2 weeks, then 50 mg for 4 weeks)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: No-loading-dose metrifonate (50 mg for 6 weeks)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Loading-dose metrifonate
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: No-loading-dose metrifonate
Number of subjects: 395
Study: 8539322

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) and (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12